{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for uracil root_notes_note in Note (approximate match)
Status:
Investigational
Source:
JAN:URACIL (2-13C) [JAN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Otsuka Pharmaceutical was developing URACIL C-13, 2- ([2-13C]uracil) breath test for diagnosis of cancer and gastric emptying disorders. Dihydropyrimidine dehydrogenase (DPD) deficiency is critical in the predisposition to 5-fluorouracil dose-related toxicity. The phenotypic [2-(13)C]uracil breath test (UraBT) demonstrated 96% specificity and 100% sensitivity for identification of DPD deficiency. Phase II development of the breath test was ongoing. As phase II clinical study didn't exploit performance as diagnostic medicines, the development of [2-13C]uracil was discontinued.
Status:
US Approved Allergenic Extract
(1972)
Source:
BLA102192
(1972)
Source URL:
First approved in 1972
Source:
BLA102192
Source URL:
Class:
MIXTURE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Allergenic Extract
(1974)
Source:
BLA102223
(1974)
Source URL:
First approved in 1974
Source:
BLA102223
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Allergenic Extract
(1974)
Source:
BLA102223
(1974)
Source URL:
First approved in 1974
Source:
BLA102223
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Allergenic Extract
(1974)
Source:
BLA102223
(1974)
Source URL:
First approved in 1974
Source:
BLA102223
Source URL:
Class:
STRUCTURALLY DIVERSE
